title: Long-term hearing loss after chemoradiation in patients with head and neck cancer.
abstract: OBJECTIVE
  The purpose of this study was to determine whether concomitant chemoradiation (CCRT)-induced hearing loss is progressive over time or not.
  
  
  METHODS
  Long-term (LT) follow-up study.
  
  
  METHODS
  Between 1999 and 2004, 158 patients with head and neck cancer were treated with intravenous (IV) CCRT (n = 80) or intraarterial CCRT (n = 78). Audiometry was performed before, short-term (ST), and LT posttreatment. Differences in hearing were assessed with a multivariable linear regression analysis, incorporating the effect of aging.
  
  
  RESULTS
  Long-term audiometry (median 4.5 years) was available in 67 patients (42%). At ST follow-up, a deterioration of 21.6 decibel was seen compared to baseline at pure-tone averages (PTA) 8-10-12.5 kHz. At LT follow-up, this deterioration further increased with 5 decibel (P = 0.005). Only in CCRT-IV patients was a significant progressive treatment-induced hearing loss seen, at PTA 8-10-12.5 kHz (P = 0.005), PTA 1-2-4 kHz air conduction (P = 0.014), and PTA 0.5-1-2 kHz bone conduction (P = 0.045).
  
  
  CONCLUSIONS
  CCRT-induced hearing impairment was progressive over time, especially in higher frequencies and only in CCRT-IV patients, with a modest deterioration of 5 decibel 4.5 years post-treatment.
  
  
  METHODS
  4.
authors: Department of Head and Neck Oncology and Surgery, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
authors: Eleonoor A R
authors: EA
authors: Theunissen
authors: Charlotte L
authors: CL
authors: Zuur
authors: Sophie C J
authors: SC
authors: Bosma
authors: Marta
authors: M
authors: Lopez-Yurda
authors: Michael
authors: M
authors: Hauptmann
authors: Sieberen
authors: S
authors: van der Baan
authors: Jan Paul
authors: JP
authors: de Boer
authors: Lisette
authors: L
authors: van der Molen
authors: Coen R N
authors: CR
authors: Rasch
authors: Wouter A
authors: WA
authors: Dreschler
authors: Alfons J M
authors: AJ
authors: Balm
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001301:Audiometry, Pure-Tone; D001309:Auditory Threshold / Q000502:physiology; D059248:Chemoradiotherapy / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D005544:Forecasting; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D006309:Hearing / Q000502:physiology* / Q000528:radiation effects*; D034381:Hearing Loss / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology*; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009426:Netherlands / Q000453:epidemiology; D012189:Retrospective Studies; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents
keywords: Chemoradiation; cisplatin; head and neck cancer; hearing loss; ototoxicity